Cardior Pharmaceuticals

Next Generation RNA based Cardiovascular Medicine

Press Release: Cardior Pharmaceuticals raises €15 million and appoints CEO and CSO

CardiorLogo
IMG_4071

Hannover, Germany, May 11th 2017 – Cardior Pharmaceuticals, today announced the completion of a €15 million Series A financing round led by LSP (Life Sciences Partners), Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (with its new BioMedInvest III Fund) and High-Tech Gründerfonds (HTGF). Cardior is pioneering its proprietary RNA technology to revolutionize predicting and treating heart failure. The molecular targets are non-coding RNAs linked to heart failure development that simultaneously control cardiac growth and calcium handling / contractility of cardiomyocytes. The targeting of certain specific non-coding RNAs reverses maladaptive cardiac remodeling and restores normal cardiac function.

Read More…

Pressemitteilung: Cardior Pharmaceuticals schliesst erfolgreich erste Finanzierungsrunde über €15 Millionen ab und ernennt CEO und CSO

Hannover, Deutschland, 11. Mai 2017 – Cardior Pharmaceuticals, ein junges deutsches Biotechnologie Unternehmen, das auf dem Gebiet von RNA-basierten Therapeutika für Patienten mit Herzerkrankungen tätig ist, gibt heute den erfolgreichen Abschluss seiner ersten Finanzierungsrunde (Serie A) mit einer Gesamtsumme von 15 €Mio bekannt. Die Finanzierungsrunde wurde von LSP (Life Sciences Partners) als Leadinvestor gemeinsam mit den Co-Investoren Boehringer Ingelheim Venture Fund (BIVF), Bristol-Myers Squibb (BMS), BioMedPartners (mit dem neuen BioMedInvest III Fund) und dem High-Tech Gründerfund (HTGF) gezeichnet. Cardior ist Vorreiter bei der Entwicklung von RNA-basierten Technologien und bei der Revolutionierung innovativer neuer Strategien zur Verhinderung und Behandlung von Herzinsuffizienz. Die molekularen Zielstrukturen umfassen sogenannte nichtkodierende Ribonukleinsäuren (RNAs), die Größenwachstum und Kontraktilität von Herzmuskelzellen kontrollieren und mechanistisch maßgeblich an der Entwicklung von Herzschwäche beteiligt sind. Die Modulation dieser zentralen Schaltermoleküle versetzt die Herzmuskelzellen erstmals in die Lage krankhafte kardiale Umbauprozesse zurückzubilden und die kardiale Funktion zu normalisieren.
Read More…

Winner of the Startup Challenge at Deutsche Biotechnologietage 2017!

Today, Cardior has been selected as Winner of the Startup Challenge at Deutsche Biotechnologietage 2017!
10 companies were selected to pitch in this competition sponsored by Johnson & Johnson and JJI.

The award includes one-year access to JLINX incubator in Beerse, Belgium including mentoring by experts from Johnson & Johnson Innovation and its network.
In addition, Bioqube Ventures offers access to a Seedfund they are managing for JJI.

Cardior Award_2017

“Landmark Research” on the role of long non-coding RNAs (lncRNAs), a novel 3D heart tissue organoid derived from stem cells and potential applications for the treatment of heart failure

From the labs of the Institute of Molecular and Translational Therapeutic Strategies at the Hannover Medical School comes more exciting research on the role of next-generation therapeutic RNA targets, published today in the Journal of the American College of Cardiology (JACC).

Titled “
Development of Long Noncoding RNA-Based Strategies to Modulate Tissue Vascularization” by Jan Fiedler et al., the article describes not only the discovery of new regulatory RNAs that play a decisive functional role in the development of blood vessels (angiogenesis) in conditions similar to those following a heart attack (low oxygen supply of heart tissue / hypoxia), but also the effect of the pharmacological modulation of these RNAs in a novel, lab-grown, heart-organoid, that represents the closest laboratory model of a human heart to this date.

This publication has been heralded as “landmark research” by renown cardiologist
Dr. Valentin Fuster in the audio commentary (download) and Martina Calore and Leon De Windt in the editorial comment published in the same issue of JACC. Dr. Fuster agreed with the authors that the concept presented in the article “could be very meaningful as a therapeutic tool” to treat heart failure and encouraged also clinical cardiologists to look beyond the complex title and learn about

these beautiful experimental models, in-vitro and ex-vivo, that we [cardiologists] are going to hear much more about in terms of the role of microRNAs, in particular long non-coding RNAs, in the regulation and therapy of a number of cardiovascular indications in the future”.

Martina Calore and Leon De Windt are equally enthusiastic about the presented data that “
adds valuable information by discovering lncRNAs that potentially achieve therapeutic neovascularization in HF [heart failure]”. They further highlighted the need for better model systems of the heart and welcomed the methodological approach of using 3-dimensional engineered heart tissue (EHT) derived from human induced pluripotent stem cells, by which “the investigators took this study another innovative step forward”.

Link to MHH Press release [in German]


FiedlerThum2
Authors Prof. Thomas Thum and Dr. Jan Fiedler

Thomas Thum appointed associate editor of the European Heart Journal

2270_full_pdf__page_1_of_6_

One of the leading scientific journals in the cardiovascular space has appointed Thomas to its editorial board. The official journal of the European Society of Cardiology currently features a publication Impact Factor of 15.2 making it the third most important journal in the Cardiovascular disease area after the "Journal of the American College of Cardiology" and "Circulation". 1

————
1 http://www.scimagojr.com/journalrank.php?category=2705